Discovery of novel treatment for intractable vasculitis

迄今为止，促进缺血组织中治疗性血管生成的临床研究仅集中在细胞疗法或血管生成生长因子的使用上。事实上，自体单核细胞被报道为治疗外周动脉疾病的潜在有效方法，其机制是基于单核细胞产生可变的细胞因子。最佳交付战略尚未确定。为了建立适用于难治性血管炎的治疗性血管生成策略，我们研究了一种可以安全治愈难治性溃疡的治疗性血管生成，利用碱性成纤维细胞生长因子应用与药物递送系统（DDS）。1年来<st>，我们报道了理想的评价临床血管生成的方法学途径。观察2 <nd>~ 3年<rd>对Churg-Strauss综合征和SLE的临床疗效。最后一年，将该疗法与骨髓单个核细胞移植治疗动脉粥样硬化闭塞症和Buerger病的效果进行比较。这些治疗各种顽固性血管炎的广泛有效的临床效果被发表在《血管炎》一书中，引起了世界各国的关注。

To date, clinical studies on promoting therapeutic angiogenesis in ischemic tissues have focused exclusively on the use of cell therapy or angiogenic growth factors. In fact, autologous mononuclear cell is reported that potential effective approach for peripheral artery disease and the mechanism is based on the production of variable cytokines from mononuclear cells. An optimal delivery strategy has not been established yet. To establish therapeutic angiogenesis strategies applying for intractable vasculitis, we investigated a therapeutic angiogenesis that could safely cure intractable ulcers, utilizing basic fibroblast growth factor application with a drug-delivery system(DDS). 1^<st> year, we reported ideal methodological approach to evaluate clinical angiogenesis. 2^<nd> to 3^<rd> year, the clinical effect for Churg-Strauss syndrome and SLE were reported. At final year, the effect of this therapy was compared with bone marrow mononuclear cells implantation for atherosclerosis obliterans and Buerger's disease. These widely effective clinical effects for variable intractable vasculitis were published to the book "Vasculitis", with attract attention from worldwide.